Responses to the EMA, Grant Funding, and Industry Networking
Dear Sir or Madam, A lot has been happening at Bioceltix recently. We are engaged in a constructive dialogue with the European Medicines Agency, sharing the Bioceltix story at key industry events, and gratefully receiving further important recognitions. We have been visiting Kraków, Bruges, the WallStreet Conference in Karpacz, and EquiMental in Warsaw. Each of […]
Important decisions, new research, networking
Good morning, Pet owners may have a brain that is biologically up to 15 years “younger” than that of people without a pet. This is suggested by findings from the Alabama Brain Study on Risk for Dementia. The analysis indicates that regular contact with a four-legged companion may be associated with better performance in cognitive […]
PLN 53 million for strategy implementation and construction of a new production plant
Good morning, Poland is a leading pet-friendly country. According to a FEDIAF report, the percentage of households with at least one dog reaches 49%. This is the second-highest figure in the EU. “Dog” is no longer just clickbait; it’s a true reflection of a social trend. The dynamics of the global market are driven by […]
Two medicines with EMA, grant awarded, webinar
Good morning, the latest report from GlobalPETS shows that we are not cutting back on the health and wellbeing of our pets. Supplements, functional diets and innovative veterinary treatments are generating growing demand worldwide. Biological therapies for companion animals are very much our specialty. And dogs? They may soon see a breakthrough drug for osteoarthritis! […]
Atopic dermatitis drug, dialogue with the EMA, mission to the USA
Good morning, we are on the verge of registering BCX-CM-J for osteoarthritis in dogs. BCX-EM for arthritis in horses has already been submitted to the European Medicines Agency. We have also published preliminary, positive results for the BCX-EM-AD product for canine atopic dermatitis. A fortunate “three” also in the overall ranking of the prestigious Stock […]
A new year, the same consistency!
Good morning! This will be a favorable year for us in many respects. Thanks to the achievement of last year’s goals, we are maintaining strong momentum toward the commercialization of innovative therapies for animals. “Consistency” is also a key word for 2025, as we have scheduled breakthrough events in the Bioceltix calendar. We are also […]